Literature DB >> 10625946

Phytate (IP6) is a powerful agent for preventing calcifications in biological fluids: usefulness in renal lithiasis treatment.

F Grases1, A Costa-Bauzá.   

Abstract

The extraordinary capacity of phytate (myo-inositol hexaphosphate), a substance present in blood, urine, interstitial and intracellular fluids, to inhibit crystallization of calcium salts (oxalate and phosphate) is discussed. Its role in preventing calcium renal stone formation is specifically presented and discussed. "In vitro" and "in vivo" experiments, as well as clinical studies clearly demonstrated that phytate plays an important role as a crystallization inhibitor of calcium salts in biological fluids and becomes a clear alternative in the treatment of calcium oxalate renal lithiasis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10625946

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  14 in total

1.  A phase 1b randomized, placebo-controlled clinical trial with SNF472 in haemodialysis patients.

Authors:  Carolina Salcedo; Pieter H Joubert; Miguel D Ferrer; Ana Z Canals; Francisco Maduell; Vicens Torregrosa; Josep Maria Campistol; Raquel Ojeda; Joan Perelló
Journal:  Br J Clin Pharmacol       Date:  2019-02-19       Impact factor: 4.335

2.  A simple and rapid colorimetric method for determination of phytate in urine.

Authors:  Antonia Costa-Bauza; F Grases; I Gomila; A Rodriguez; R M Prieto; F Tur
Journal:  Urol Res       Date:  2012-04-05

3.  p21/Cip1 and p27/Kip1 Are essential molecular targets of inositol hexaphosphate for its antitumor efficacy against prostate cancer.

Authors:  Srirupa Roy; Mallikarjuna Gu; Kumaraguruparan Ramasamy; Rana P Singh; Chapla Agarwal; Sunitha Siriwardana; Robert A Sclafani; Rajesh Agarwal
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

4.  First-time-in-human randomized clinical trial in healthy volunteers and haemodialysis patients with SNF472, a novel inhibitor of vascular calcification.

Authors:  J Perelló; P H Joubert; M D Ferrer; A Z Canals; S Sinha; C Salcedo
Journal:  Br J Clin Pharmacol       Date:  2018-10-03       Impact factor: 4.335

5.  Effects of Mediterranean diets with low and high proportions of phytate-rich foods on the urinary phytate excretion.

Authors:  Rafael M Prieto; M Fiol; J Perello; R Estruch; E Ros; P Sanchis; F Grases
Journal:  Eur J Nutr       Date:  2010-01-28       Impact factor: 5.614

6.  Effects of Myo-inositol Hexaphosphate (SNF472) on Bone Mineral Density in Patients Receiving Hemodialysis: An Analysis of the Randomized, Placebo-Controlled CaLIPSO Study.

Authors:  David A Bushinsky; Paolo Raggi; Jordi Bover; Markus Ketteler; Antonio Bellasi; Mariano Rodriguez; Smeeta Sinha; Rekha Garg; Joan Perelló; Alex Gold; Glenn M Chertow
Journal:  Clin J Am Soc Nephrol       Date:  2021-04-07       Impact factor: 8.237

Review 7.  Renal lithiasis and nutrition.

Authors:  Felix Grases; Antonia Costa-Bauza; Rafel M Prieto
Journal:  Nutr J       Date:  2006-09-06       Impact factor: 3.271

8.  Inositol hexakisphosphate inhibits osteoclastogenesis on RAW 264.7 cells and human primary osteoclasts.

Authors:  María del Mar Arriero; Joana M Ramis; Joan Perelló; Marta Monjo
Journal:  PLoS One       Date:  2012-08-14       Impact factor: 3.240

Review 9.  Nutritional Management of Kidney Stones (Nephrolithiasis).

Authors:  Haewook Han; Adam M Segal; Julian L Seifter; Johanna T Dwyer
Journal:  Clin Nutr Res       Date:  2015-07-31

10.  Characterization of SNF472 pharmacokinetics and efficacy in uremic and non-uremic rats models of cardiovascular calcification.

Authors:  Miguel D Ferrer; Markus Ketteler; Fernando Tur; Eva Tur; Bernat Isern; Carolina Salcedo; Pieter H Joubert; Geert J Behets; Ellen Neven; Patrick C D'Haese; Joan Perelló
Journal:  PLoS One       Date:  2018-05-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.